efficacy and safety of pasireotide LAR 40 and 60 mg versus octreotide LARor lanreotide ATG in patients with inadequately controlled acromegaly

Phase 1

• Conditions: Acromegaly is characterized by chronic hypersecretion of growth hormone (GH), clinical features comprise structural and functional changes occurring in practically all organs. Cardiovascular disease is the main reason for morbidity and increased mortality.; MedDRA version: 17.1Level: PTClassification code 10000599Term: AcromegalySystem Organ Class: 10014698 - Endocrine disorders; Therapeutic area: Diseases [C] - Hormonal diseases [C19]

• Registration Number: EUCTR2009-016722-13-BE
• Lead Sponsor: ovartis Pharma Services AG

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2010-06-22
• Last Update Posted: 3 April 2017

Recruitment & Eligibility

• Status: ot Recruiting
• Sex: All
• Target Recruitment: 219

Inclusion Criteria

•Male and female patients = 18 years of age
•Patients with written informed consent prior to any study related activity
•Patients with inadequately controlled acromegaly as defined by
•a mean GH concentration of a 5-point profile over a 2-hour period > 2.5 µg/L
and
•sex- and age adjusted IGF-1 > 1.3 x upper limit of normal (ULN)
•Patients treated with maximum indicated doses of octreotide LAR or lanreotide ATG for at least 6 months prior to Visit 1 (Screening). The maximum indicated dose for octreotide LAR is 30 mg and for lanreotide ATG is 120 mg
•Patients with diagnosis of pituitary micro- or macro adenoma. Patients can have been previously submitted to surgery

Additional inclusion criteria as per full protocol may apply
Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range 119
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range 100

Exclusion Criteria

1.Patients who have received pasireotide (SOM 230) prior to enrolment
2. Concomitant treatment with Growth Hormone Receptor (GHR)-
antagonist or dopamine agonists unless concomitant treatment was
discontinued 8 weeks prior to visit 1 (screening)(8 weeks wash out
period). Such patients must have been treated with octreotide LAR 30
mg or lanreotide ATG 120 mg monotherapy continuously for a minimum
of 6 months prior to starting combination therapy and they should have
been inadequately controlled on monotherapy.
3. Patients with compression of the optic chiasm causing acute clinically
significant visual field defects
4. Patients who require a surgical intervention for relief of any sign or
symptom associated with tumor compression
5. Patients who have received pituitary irradiation within 10 years prior
to visit 1 (screening).
6. Patients who have undergone major surgery/surgical therapy for any
cause within 4 weeks prior to visit 1 (screening).
7. Patients who are hypothyroid and not adequately treated with a stable
dose of thyroid hormone replacement therapy
Other protocol-defined exclusion criteria may apply

Study & Design

• Study Type: Interventional clinical trial of medicinal product
• Study Design: Not specified